Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales fréquentes
Nom anglais: Cytochrome P-450 CYP2C9 Inducers
Descriptor UI:D065698
Tree Number:D27.505.519.349.320
Termes MeSH sélectionnés :
Sensitivity and Specificity
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2C9 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2C9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-07",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065698",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Miklós Poór",
"url": "https://questionsmedicales.fr/author/Mikl%C3%B3s%20Po%C3%B3r",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu."
}
},
{
"@type": "Person",
"name": "Jian-Ping Cai",
"url": "https://questionsmedicales.fr/author/Jian-Ping%20Cai",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Slávka Bodnárová",
"url": "https://questionsmedicales.fr/author/Sl%C3%A1vka%20Bodn%C3%A1rov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Eszter Fliszár-Nyúl",
"url": "https://questionsmedicales.fr/author/Eszter%20Flisz%C3%A1r-Ny%C3%BAl",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Jian Liu",
"url": "https://questionsmedicales.fr/author/Jian%20Liu",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Sensitivity and Specificity of Body Mass Index for Sarcopenic Dysphagia Diagnosis among Patients with Dysphagia: A Multi-Center Cross-Sectional Study.",
"datePublished": "2022-10-26",
"url": "https://questionsmedicales.fr/article/36364757",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu14214494"
}
},
{
"@type": "ScholarlyArticle",
"name": "Improvement of nested reverse transcription-polymerase chain reaction (RT-PCR) with high specificity and sensitivity detection of sapovirus in food matrix.",
"datePublished": "2022-08-24",
"url": "https://questionsmedicales.fr/article/36028003",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jviromet.2022.114609"
}
},
{
"@type": "ScholarlyArticle",
"name": "Highly sensitive and specific electrochemical biosensor for direct detection of hepatitis C virus RNA in clinical samples using DNA strand displacement.",
"datePublished": "2024-10-11",
"url": "https://questionsmedicales.fr/article/39394401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-74454-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sensitivity and specificity of OraQuick® HIV self-test compared to a 4th generation laboratory reference standard algorithm in urban and rural Zambia.",
"datePublished": "2022-05-25",
"url": "https://questionsmedicales.fr/article/35614397",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12879-022-07457-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Application of a low-cost, specific, and sensitive loop-mediated isothermal amplification (LAMP) assay to detect Plasmodium falciparum imported from Africa.",
"datePublished": "2022-10-29",
"url": "https://questionsmedicales.fr/article/36374724",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.molbiopara.2022.111529"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"item": "https://questionsmedicales.fr/mesh/D065698"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2C9 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment identifier un inducteur du CYP2C9 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2C9 ?\nQuels signes indiquent une induction du CYP2C9 ?\nComment les interactions médicamenteuses sont-elles diagnostiquées ?\nQuels médicaments sont souvent des inducteurs du CYP2C9 ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Sensitivity+and+Specificity&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?\nComment l'induction du CYP2C9 affecte-t-elle les médicaments ?\nQuels effets secondaires peuvent survenir ?\nLes symptômes varient-ils selon les patients ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Sensitivity+and+Specificity&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment prévenir l'induction du CYP2C9 ?\nLes patients doivent-ils informer leur médecin des médicaments ?\nDes tests génétiques peuvent-ils aider à la prévention ?\nComment éduquer les patients sur les inducteurs ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Sensitivity+and+Specificity&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?\nQuels médicaments peuvent être utilisés pour contrer l'induction ?\nComment surveiller l'efficacité du traitement ?\nQuels sont les risques d'un traitement inapproprié ?\nLes changements de traitement doivent-ils être rapides ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Sensitivity+and+Specificity&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?\nComment l'induction affecte-t-elle la santé globale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme ?\nComment gérer les complications liées à l'induction ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Sensitivity+and+Specificity&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels sont les principaux facteurs de risque d'induction ?\nLa génétique joue-t-elle un rôle dans l'induction ?\nLes habitudes alimentaires influencent-elles l'induction ?\nLes maladies hépatiques augmentent-elles le risque ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Sensitivity+and+Specificity&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2C9 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des antécédents médicamenteux et des tests de métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2C9 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pharmacogénétique et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2C9 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2C9 peut être un signe."
}
},
{
"@type": "Question",
"name": "Comment les interactions médicamenteuses sont-elles diagnostiquées ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont diagnostiquées par l'examen des interactions dans les bases de données médicales."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent des inducteurs du CYP2C9 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et certains anticonvulsivants sont des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de sous-dosage des médicaments, comme une douleur persistante, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment l'induction du CYP2C9 affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire l'efficacité des médicaments, entraînant des symptômes de la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires liés à un sous-dosage, comme des convulsions, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la génétique et des médicaments pris."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques comme une réponse insuffisante au traitement peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2C9 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses est essentiel."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils informer leur médecin des médicaments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin de tous les médicaments pris aide à prévenir les interactions."
}
},
{
"@type": "Question",
"name": "Des tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier les patients à risque d'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sur les médicaments inducteurs et leurs effets est cruciale pour la prévention."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie, comme une alimentation saine, peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être nécessaire d'augmenter la dose des médicaments affectés pour compenser."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent être utilisés pour contrer l'induction ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs du CYP2C9 peuvent être utilisés pour réduire l'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des tests réguliers des niveaux de médicaments dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'un traitement inapproprié ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement inapproprié peut entraîner des complications graves, comme des crises épileptiques."
}
},
{
"@type": "Question",
"name": "Les changements de traitement doivent-ils être rapides ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les changements doivent être faits prudemment pour éviter des effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des crises convulsives ou une résistance au traitement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle la santé globale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut compromettre la santé en rendant les traitements moins efficaces, aggravant les maladies."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un ajustement approprié du traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques à long terme incluent des maladies chroniques dues à un traitement inefficace."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier et des ajustements de traitement basés sur les symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments, l'alcool et des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "La génétique joue-t-elle un rôle dans l'induction ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent influencer l'activité du CYP2C9 et son induction."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles l'induction ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires, comme la consommation de pamplemousse, peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques peuvent augmenter le risque d'induction du CYP2C9."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions entre médicaments peuvent augmenter le risque d'induction enzymatique."
}
}
]
}
]
}
The accuracy of body mass index (BMI) for sarcopenic dysphagia diagnosis, which remains unknown, was evaluated in this study among patients with dysphagia. We conducted a 19-site cross-sectional study...
Sapovirus (SaV) is a causative agent of human gastroenteritis in both community outbreaks and sporadic cases worldwide. Shellfish accumulate a variety of pathogens during filter feeding. In particular...
Hepatitis C virus (HCV) is a common blood-borne infection that can lead to long-term illnesses such as hepatocellular cancer and liver cirrhosis. Early diagnosis is crucial for effective management, a...
HIV self-testing (HIVST) has the potential to increase coverage of HIV testing, but concerns exist about intended users' ability to correctly perform and interpret tests, especially in poor communitie...
Participants were recruited from randomly selected rural and urban households and one urban health facility between May 2016 and June 2017. Participants received a brief demonstration of the self-test...
Initial piloting showed that written instructions alone were inadequate, and a demonstration of self-test use was required. Of 2,566 self-test users, 2,557 (99.6%) were able to interpret their result....
Self-testers in Zambia who used OraQuick® HIV Self-Test achieved reasonable clinical performance compared to the national RDT algorithm. However, sensitivity of the self-test was reduced compared to a...
Chinese citizens traveling abroad bring back imported malaria cases to China. Current malaria diagnostic tests, including microscopy and antigen-detecting rapid tests, cannot reliably detect low-densi...
We developed a miniaturized LAMP assay to amplify the actin I gene of P. falciparum. Each reaction consumed only 25% of the reagents used in a conventional LAMP assay and the same amount of DNA templa...
The new LAMP assay was highly sensitive and detected two more malaria cases than nested PCR. Compared to nested PCR, the sensitivity and specificity of the novel LAMP assay were 100% [95% confidence i...
The novel LAMP assay based on the P. falciparum actin I gene was specific, sensitive, and cost-effective, as it consumes 1/4 of the reagents in a typical LAMP reaction....
We aimed to evaluate cutoff values of immunoreactive trypsinogen (IRT)/IRT and determine relationship between IRT values and clinical characteristics of children with cystic fibrosis (CF). This study ...
Cervical carcinoma (CC) is the fourth most common malignancy among women. Screening with Papanicolau smear is linked to a reduction in CC incidence rates when screening programs have been developed. H...
This study was performed to validate a dried blood spot (DBS) method for the serological screening of HIV, syphilis, hepatitis B and C. It included 250 paired DBS and serum samples and 116 unpaired DB...
Asthma is the most common chronic disease in children and a robust diagnosis is crucial to optimize patient care and reduce its burden. To diagnose asthma in children, the Global Initiative for Asthma...
The objective of this study was to evaluate the sensitivity of spirometric and clinical parameters in identifying children with possible asthma....
The VERI-VEMS Study is a multicenter international retrospective cohort study. Data were collected, from January 2008 until January 2019, for all consecutive children (aged 5-18 years), with a diagnos...
The study included 871 children. The reversibility criterion of 12% of FEV...
Postbronchodilator reversibility of 12%, although essential for patients' follow-up, has an insufficient low sensitivity in reaching a diagnosis of asthma in pediatric patients, compared with a combin...
Most studies assessing the sensitivity and specificity of caries detection methods have been performed in vitro using the histological method as the gold standard showing inconsistent values. The aim ...
One hundred sixty children, ages 7-12 years, participated in the study. Five zones in the occlusal surfaces of 859 primary and 632 first permanent molars were examined visually using ICDAS-II, the RM ...
For all molars combined and for primary molars only, the sensitivity of ICDAS II was higher for detecting total caries (p < 0.001), caries in enamel (p < 0.001), and caries in dentin (p = 0.016), but ...
The sensitivity and specificity of ICDAS II and RM changes depending on whether the carious lesion compromises the enamel or dentin, and if the caries detection is performed in the primary molars or p...